

# News Releases

All Years

Search

Go

[Advanced Search](#)

**MAR 24, 2022**

**Inhibrx Announces Details of Presentations at 2022 AACR Annual Meeting**

**FEB 28, 2022**

**Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Recent Corporate Highlights**

**FEB 22, 2022**

**Inhibrx Announces Amended Loan Agreement with Oxford**

**JAN 4, 2022**

**Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data**

**DEC 1, 2021**

**Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma**

Show  per page

[«](#) [1](#) [...](#) [7](#) [8](#) [9](#) [10](#) [11](#) [12](#) [13](#) [...](#) [16](#) [»](#)



